Research Articles | Page 34 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes Jan 2020 The New England Journal of Medicine Myelodysplastic Syndromes (MDS)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Mar 2021 The New England Journal of Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Apr 2023 The Oncologist Myelodysplastic Syndromes (MDS)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Apr 2023 The Oncologist Myelodysplastic Syndromes (MDS)
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria Sep 2019 Therapeutic Advances in Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Treatment options for lower-risk myelodysplastic syndromes. Where are we now? Jan 2021 Therapeutic Advances in Hematology Myelodysplastic Syndromes (MDS)
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis Dec 2023 Therapeutic Advances in Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study Oct 2020 Therapeutic Advances in Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Management of myelodysplastic syndromes after failure of response to hypomethylating agents May 2019 Therapeutic Advances in Hematology Myelodysplastic Syndromes (MDS)
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care Apr 2023 Transplantation and Cellular Therapy Myelodysplastic Syndromes (MDS)